ALQGC.PA - Quantum Genomics Societe Anonyme

Paris - Paris Prix différé. Devise en EUR
2,2300
+0,0150 (+0,68 %)
À partir de 12:48PM CEST. Marché ouvert.
Le graphique des titres n’est pas pris en charge par votre navigateur actuel
Clôture précédente2,2150
Ouverture2,2350
Offre0,0000 x 0
Vente0,0000 x 0
Var. jour2,1800 - 2,3000
Sur 52 semaines1,5100 - 6,1000
Volume104 969
Volume moyen225 730
Cap. boursière41,762M
Bêta (mensuel sur 5 ans)0,30
Rapport P/E (sur 12 mois)S.O.
BPA (sur 12 mois)-0,5030
Date de bénéficesS.O.
Dividende et rendement à termeS.O. (S.O.)
Date ex-dividendeS.O.
Objectif sur 1 an9,86
  • Globe Newswire

    Quantum Genomics Secured New Financing, Published its Financial Statements for Fiscal Year 2019 and Provides 2019 Highlights

    * Despite the current public health crisis and any financial consequences it may have, the fact that Quantum Genomics has secured new financing confirms that investors remain confident in its outlook. * This round of financing, which includes a loan not to exceed €8 million and the issue of share subscription warrants, was secured as part of an agreement with Negma Group Ltd, dated March 26, 2020. * This financing will be renewable two times, by mutual consent between Quantum Genomics and Negma Group Ltd, and will provide Quantum Genomics with a maximum of €24 million. * This marks the end of guaranteed structured equity financing from Kepler Cheuvreux. * Review of Fiscal Year 2019 * Continued clinical research and launch of Phase III for difficult-to-treat and resistant arterial hypertension. * First regional partnership signed with a leading laboratory in South America.PARIS and NEW YORK, March 31, 2020 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult-to-treat and resistant hypertension and heart failure, announces the implementation of a financing solution to secure the successful completion of ongoing clinical studies that has become uncertain and has published its annual financial statements, approved by the board of directors at its last meeting on March 25, 2020.Jean-Philippe Milon, CEO of Quantum Genomics, states: “Throughout fiscal year 2019, Quantum Genomics has continued to pursue research projects, with two major highlights: the transition to Phase III of our pivotal study on difficult-to-treat and resistant arterial hypertension in December, and the conclusion of an exclusive licensing agreement with Biolab Sanus Pharmaceutical to develop and distribute firibastat to treat arterial hypertension in Latin America. As previously mentioned, this initial partnership will open the door to new contracts. We are currently in negotiations with several other laboratories, especially in Asia. Despite the ongoing public health crisis, talks will continue, though any final decision may be postponed. In order to protect our research programs and ensure their continuation, regardless of the long-term consequences of the current crisis, we have secured additional financial resources.”Securing Financing Given the current public health crisis, and in order to prepare for its financial consequences, Quantum Genomics (the “Company”) has secured new financing thanks to an agreement with Negma Group Ltd, dated March 26, 2020. This agreement will provide a maximum of €8 million initially, renewable twice, by mutual consent between the Company and Negma Group Ltd, for a maximum total of €24 million.Benoît Gueugnon, CFO, explains: “Although our financial situation allows us to meet our commitments over 12 months, we prefer to adopt a prudent position by securing a maximum of €24 million in the form of loans with share warrants. This will allow us to guarantee that our research programs will continue. This highlights Quantum Genomics’ reliability and attractiveness for financial investors, despite a difficult context. The conditions obtained will limit both the dilutive effect and the impact of stock market volatility. In the current context, it seems reasonable to secure our resources as much as possible, especially since this financing can be interrupted at any time, notably at the Company’s request, if the overall situation returns to normal. Management and the board of directors of Quantum Genomics have chosen this course of action to ensure the continuity of our activities.”Transaction Characteristics The financing agreement reached with Negma Group Ltd for a total amount not to exceed €8,000,000 includes a loan (the “Loan”) whose main terms are as follows: * The Loan will not bear interest. * The Loan will be distributed in four installments of €2,000,000 each, transferred every 30 trading days (except when this period is automatically extended in certain instances as laid out in the agreement, or when the Company decides to notify Negma Group Ltd that it would like to suspend payments). * Each Loan installment has a 12-month maturity. * 5,000,000 share subscription warrants will be issued by the Company the day the first installment is received, which should be in the next few days, given Resolution 18 from the Company’s general meeting on June 27, 2019. Additional share subscription warrants may be issued by the Company, at its discretion, to Negma Group Ltd if the initial issue is not enough to cover the Loan. * Loan installments will be repaid by offsetting them with share subscription warrants exercised at the price Negma Group Ltd has agreed to pay, up to €8,000,000 (except in the case that the financing agreement is renewed). As a result, any excess warrants may not be converted by Negma Group Ltd after the entirety of the Loan has been repaid, since any shares created to cover warrants may only be issued to offset all or part of the Loan effectively distributed, but not yet repaid. * The exercise price for the warrants will be equal to 96% of the lowest average stock price weighted by share volume for the Company’s shares, as published by Bloomberg, across the last five trading sessions during which Negma Group Ltd has not traded Quantum Genomics shares, i.e. at a 4% discount. * Quantum Genomics SA will have the option to repay the Loan early, in whole or in part, at its nominal value plus a 4% premium. * Until the end of the term of the financing agreement, Negma Group Ltd will not be allowed to more than 16% of the total value of exercised Quantum Genomics shares sell on the market for a period of 20 consecutive trading days. * To pay a portion of Negma Group Ltd’s commitment commission, the Company has issued 2,702 shares to Negma Group Ltd. These shares were issued at an issue price of €1.85 per share based on Resolution 18 from the Company’s general meeting on June 27, 2019. * Both parties have agreed that the financing agreement may be renewed two times under the same conditions by mutual consent. * The Investor does not intend to retain a permanent stake in the Company.Dilutive Effect For information purposes, if all 5,000,000 warrants issued to Negma Group Ltd are converted, a shareholder owning 1.00% of Quantum Genomics’ share capital before this financing solution will see their stake reduced to 0.79% of the Company’s share capital (based on the Company’s €7,443,643.93 in share capital, currently divided into 18,617,524 shares).Prospectus This transaction did not include the publication of a prospectus submitted for approval to the AMF.Quantum Genomics’ advisors for this transaction: Financial advisor: Scalene Partners (www.scalenepartners.com) – Simon Eischen, Samuel Assaraf Legal advisor: Orsay Avocats (www.orsaylaw.com) – Frédéric Lerner, Pierre HesnaultReview of Fiscal Year 2019: Significant Events Fiscal year 2019 saw our research programs on arterial hypertension enter Phase III, as well as the creation of our first regional partnership with Biolab Sanus Pharmaceutical, one of the five largest pharmaceutical laboratories in Brazil. This exclusive licensing and collaboration agreement aims to develop and distribute firibastat in Latin America. With more than 140 products in their portfolio and a strong focus on hypertension, Biolab Sanus Pharmaceutical is the ideal partner in this market.Also in relation to arterial hypertension, Quantum Genomics launched its pivotal Phase III study, named FRESH (Firibastat in treatment-RESistant Hypertension). This is the last stage to complete before firibastat can be put on the market. The first patients will be recruited for the study soon, and the study’s first effectiveness results are expected in the second half of 2021. This study is being conducted in partnership with the Biolab Sanus Pharmaceutical laboratory, which will cover any costs related to recruiting patients in Latin America, roughly 20% of the 500 patients in the study.In terms of heart failure, in June, Quantum Genomics recruited its first patients for the Phase IIb QUORUM study, which aims to measure firibastat’s effectiveness and tolerance to ramipril1 in patients after an acute myocardial infarction. This multi-national study will be conducted in around forty clinical centers, with results expected in the second half of 2020.Quantum Genomics is running a parallel study to confirm that firibastat can be used to treat arterial hypertension (especially resistant hypertension) or heart failure, even in cases with associated renal failure.2019 Annual Financial Statements and Cash Position The financial statements for fiscal year 2019 show -€10.8 million in operating income, compared to -€13.6 million a year earlier due to lower spending related to the end of the Phase IIb NEW-HOPE study. After including the research tax credit, worth €1.5 million, net income stood at -€9.1 million, compared to -€12.0 million the previous year.Free cash flow (net cash from operating activities) was -€10.7 million during this period.At the end of December 2019, the Company had €10.2 million in equity, plus €0.7 million in other equity (subsidized loans from Bpifrance). The Company has no financial liabilities and available cash flow reached €11.2 million, compared to €14.8 million at December 31, 2018.Financial Summary at December 31, 2019:Figures in thousands of € (French standards)12/31/201912/31/2018 Revenue361.171.3 Personnel costs(2,775.6)(2,402.6) Other operating expenses(8,345.5)(11,266.7) Operating income(10,760.0)(13,598.1) Financial income (expense)11.0104.0 Earnings before tax(10,749.1)(13,494.1) Non-recurring income (expense) 123.445.7 Research tax credit1,547.21,458.4 Net income(9,078.4)(11,990.1) Publication of the Annual Financial ReportThe annual financial report, including financial statements at December 31, 2019, the management report and statutory auditors report are available on the Company’s website: www.quantum-genomics.com.End of Guaranteed Structured Equity Financing from Kepler CheuvreuxQuantum Genomics secured equity financing in March 2018 with Kepler Cheuvreux. The last drawdown was executed in March 2020, creating 110,000 shares. In total, this line of financing allowed the Company to raise €24 million to finance its research programs on difficult-to-treat and resistant arterial hypertension and heart failure.Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. The company relies on 20 years of academic research from the Paris-Descartes University and the laboratory directed by Dr. Catherine Llorens-Cortes at the Collège de France (French National Institute of Health and Medical Research (INSERM)/ the Scientific Centre for National Research (CNRS)). The goal of Quantum Genomics is to develop innovative treatments for complicated, or even resistant, cases of hypertension (around 30% of patients have poor control of their condition or receive ineffective treatment) and for heart failure (one in two patients diagnosed with severe heart failure dies within five years).Based in Paris and New York, Quantum Genomics is listed on the Euronext Growth exchange in Paris (FR0011648971- ALQGC) and trades on the OTCQX Best Market in the United States (symbol: QNNTF)For more information, please visit www.quantum-genomics.com, or follow us on Twitter and LinkedInContacts Quantum Genomics  Jean-Philippe Milon CEO jean-philippe.milon@quantum-genomics.comBenoît Gueugnon CFO benoit.gueugnon@quantum-genomics.com    So Bang (Europe)   Nathalie Boumendil Financial Communications +33 (0)6 85 82 41 95 | nathalie@so-bang.frSamuel Beaupain Media Relations and Scientific Communications +33 (0)6 88 48 48 02 | samuel@so-bang.fr    LifeSci (USA)  Dan Ferry Financial Communications +1 (617) 535-7746 | Daniel@lifesciadvisors.comMike Tattory Media Relations and Scientific Communications +1 (609) 802-6265 | mtattory@lifescipublicrelations.com ____________________ 1 Ramipril is an ACE (Angiotensin-Converting Enzyme) inhibitor, the standard treatment for heart failure, including for patients who develop heart failure after an acute myocardial infarction

  • Globe Newswire

    Quantum Genomics Appoints Benoît Gueugnon as Vice President of Finance

    PARIS and NEW YORK, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC, OTCQX - QNNTF), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult-to-treat and resistant hypertension and heart failure, today announced the appointment of Benoît Gueugnon as Vice-President Finance. He will succeed Marc Karako who is leaving the Company. Benoît graduated from the Normandy Business School and holds a Masters II Degree in Audit & Corporate Finance. Benoît brings strong financial experience to Quantum Genomics senior management team, having previously served as Senior Financial Auditor at KPMG Paris. He joined Quantum Genomics in 2018 as Group Financial Controller and worked closely with Marc Karako.Jean-Philippe Milon, Chief Executive Officer of Quantum Genomics said: « I thank Benoît, who since beginning with Quantum Genomics in 2018, has demonstrated enthusiasm and his efficiency, particularly in driving the execution of Quantum Genomic’s recently signed partnership with Biolab. I am very pleased to promote him to this strategic position. His energy and skillset are strong assets for our Company. »Benoît Gueugnon commented: “I express my gratitude to Jean-Philippe, the Quantum Genomics management team and its board of directors for this opportunity. I look forward to continue supporting Quantum Genomics in this new capacity, and at this exciting time for the Company in which it is launching a Phase III clinical trial in difficult-to-treat and resistant hypertension, and looks to sign new partnerships in 2020.”\- Picture available on request -About Quantum GenomicsQuantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. The company relies on 20 years of academic research from the Paris-Descartes University and the laboratory directed by Dr. Catherine Llorens-Cortes at the Collège de France (French National Institute of Health and Medical Research (INSERM)/ the Scientific Centre for National Research (CNRS)). The goal of Quantum Genomics is to develop innovative treatments for complicated, or even resistant, cases of hypertension (around 30% of patients have poor control of their condition or receive ineffective treatment) and for heart failure (one in two patients diagnosed with severe heart failure dies within five years).Based in Paris and New York, Quantum Genomics is listed on the Euronext Growth exchange in Paris (FR0011648971- ALQGC) and trades on the OTCQX Best Market in the United States (symbol: QNNTF). For more information, please visit www.quantum-genomics.com, or follow us on Twitter and LinkedIn.Contacts     Quantum Genomics  Jean-Philippe MilonBenoît Gueugnon CEO CFO jean-philippe.milon@quantum-genomics.combenoit.gueugnon@quantum-genomics.com    So Bang (Europe)   Nathalie BoumendilSamuel Beaupain Financial CommunicationsMedia Relations and Scientific Communications +33 (0)6 85 82 41 95 | nathalie@so-bang.fr+33 (0)6 88 48 48 02 | samuel@so-bang.fr    LifeSci (USA)  Dan FerryMike Tattory Financial CommunicationsMedia Relations and Scientific Communications +1 (617) 535-7746 | Daniel@lifesciadvisors.com+1 (609) 802-6265 | mtattory@lifescipublicrelations.com

  • Globe Newswire

    Quantum Genomics to Present at the Gordon Research Conference 2020 Dedicated to the Renin Angiotensin Aldosterone System

    PARIS and NEW YORK, Jan. 15, 2020 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC, OTCQX - QNNTF), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat resistant hypertension and heart failure, today announced it will share preclinical results of firibastat in heart failure post myocardial ischemia during an oral presentation at the Gordon Research Conference being held from February 8-14, 2020 in Barga, Italy. Dr. Solene Boitard-Joanne, Pharmacology Department of Quantum Genomics, will present preclinical results of firibastat in mice after myocardial infarction, obtained in collaboration with the INSERM laboratory directed by Dr. Catherine Llorens-Cortès at the Collège de France. The results, published recently in the Journal of Molecular and Cellular Cardiology, demonstrate the efficacy of firibastat in improving cardiac function and preventing the onset of heart failure after a myocardial infarction (Boitard et al, 2019).Oral presentation details Study Title: Brain Renin-Angiotensin System Blockade with Firibastat, an Orally Active, Central Acting Aminopeptidase A Inhibitor Prodrug Prevents Cardiac Dysfunction After Myocardial Infarction in MiceDate: February 9th, 2020Time: 10:20 am – 10:40 am CETSession: Angiotensin Beyond Hypertension: Existing and Novel TherapiesChairs: Dr. Augusto Peluso and Dr. Maira SoitoThe Gordon Research Conference "Angiotensin" is a prestigious scientific congress, bringing together researchers and scientific experts from around the world, where the latest discoveries and advances in the field of the renin angiotensin aldosterone system (RAAS) are presented. The 2020 session chaired by Prof. Maria Luisa Sequeira-Lopez and Prof. Minolfa C. Prieto will be devoted more specifically to the integration of new technological advances, clinical trials and personalized therapeutic approaches for health.Financial calendarQuantum Genomics is also announcing its financial timetable for the year 2020:March 26, 2020 after tradingPublication of Financial Year 2019 Results June 25, 2020 at 10:00 amShareholders General Meeting October 1, 2020 after tradingPublication of Results for the 1st Half of 2020 About Quantum GenomicsQuantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. The company relies on 20 years of academic research from the Paris-Descartes University and the laboratory directed by Dr. Catherine Llorens-Cortes at the Collège de France (French National Institute of Health and Medical Research (INSERM)/ the Scientific Centre for National Research (CNRS)). The goal of Quantum Genomics is to develop innovative treatments for complicated, or even resistant, cases of hypertension (around 30% of patients have poor control of their condition or receive ineffective treatment) and for heart failure (one in two patients diagnosed with severe heart failure dies within five years).Based in Paris and New York, Quantum Genomics is listed on the Euronext Growth exchange in Paris (FR0011648971- ALQGC) and trades on the OTCQX Best Market in the United States (symbol: QNNTF)For more information, please visit www.quantum-genomics.com, or follow us on Twitter and LinkedInContact information  Quantum Genomics  Jean-Philippe Milon CEO +33 (0)1 85 34 77 70 | jean-philippe.milon@quantum-genomics.comMarc Karako CFO - Investor Relations +33 (0)1 85 34 77 70 | marc.karako@quantum-genomics.com    So Bang (Europe)  Nathalie Boumendil Financial Communications +33 (0)6 85 82 41 95 | nathalie@so-bang.frSamuel Beaupain Media Relations and Scientific Communications +33 (0)6 88 48 48 02 | samuel@so-bang.fr    LifeSci (USA)  Dan Ferry Financial Communications +1 (617) 535-7746 | Daniel@lifesciadvisors.comMike Tattory Media Relations and Scientific Communications +55 11 3573 6316 | mtattory@lifescipublicrelations.com

  • Globe Newswire

    Quantum Genomics Initiates its Pivotal Phase III FRESH Trial in Difficult-to-Treat and Resistant Hypertension

    PARIS and NEW YORK, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC, OTCQX - QNNTF), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat resistant hypertension and heart failure, today announced the initiation of its pivotal Phase III FRESH study (Firibastat in treatment-RESistant Hypertension) in difficult-to-treat1 and resistant2 hypertension. The trial is being conducted in partnership with Biolab Sanus Pharmaceuticals, as announced on December 9, 2019. This efficacy study will enroll 500 subjects with difficult-to-treat or resistant hypertension who will be randomized to receive a blind treatment with firibastat (500 mg BID), or placebo, for three months on top of their current therapy, in approximately 70 hospitals worldwide. The primary endpoint is change from baseline in systolic automated office blood pressure.The trial is being conducted in Europe (France, Germany, Poland, Spain and Czech Republic), Canada, USA and Latin America (Brazil & Mexico), with the support of the CROs (Contract Research Organisations) PRA Health sciences for Europe, Canada and the US and Azidus for Latin America.Biolab Sanus Pharmaceuticals will be responsible for trial costs in Latin America, which will account for approximately 100 (20%) of the 500 patients enrolled in the study.The final protocol has been completed, site selection is ongoing and regulatory (ethic committees and competent authorities) files are in preparation for each country. The first patient enrollment is expected in the first quarter of 2020 and top-line efficacy results are anticipated in the second half of 2021.(1) Patients not controlled despite two antihypertensive classes, including a diuretic, at maximum tolerated doses.(2) Patients not controlled despite at least three antihypertensive classes, including a diuretic, at maximum tolerated doses.About Quantum GenomicsQuantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. The company relies on 20 years of academic research from the Paris-Descartes University and the laboratory directed by Dr. Catherine Llorens-Cortes at the Collège de France (French National Institute of Health and Medical Research (INSERM)/ the Scientific Centre for National Research (CNRS)). The goal of Quantum Genomics is to develop innovative treatments for complicated, or even resistant, cases of hypertension (around 30% of patients have poor control of their condition or receive ineffective treatment) and for heart failure (one in two patients diagnosed with severe heart failure dies within five years).Based in Paris and New York, Quantum Genomics is listed on the Euronext Growth exchange in Paris (FR0011648971- ALQGC) and trades on the OTCQX Best Market in the United States (symbol: QNNTF).For more information, please visit www.quantum-genomics.com, or follow us on Twitter and LinkedInContact informationQuantum Genomics  Jean-Philippe Milon CEO +33 (0)1 85 34 77 70 | jean-philippe.milon@quantum-genomics.comMarc Karako CFO - Investor Relations +33 (0)1 85 34 77 70 | marc.karako@quantum-genomics.com So Bang (Europe)   Nathalie Boumendil Financial Communications +33 (0)6 85 82 41 95 | nathalie@so-bang.frSamuel Beaupain Media Relations and Scientific Communications +33 (0)6 88 48 48 02 | samuel@so-bang.fr LifeSci (USA)  Dan Ferry Financial Communications +1 (617) 535-7746 | Daniel@lifesciadvisors.comMike Tattory Media Relations and Scientific Communications +55 11 3573 6316 | mtattory@lifescipublicrelations.com

  • Globe Newswire

    Quantum Genomics to Participate in Biotech Showcase 2020

    PARIS and NEW YORK, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC, OTCQX - QNNTF), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat resistant hypertension and heart failure, announces its participation in Biotech Showcase 2020 in San Francisco, being held on January 13-15, 2020, in parallel to the annual J.P. Morgan Healthcare Conference.  On this occasion, Quantum Genomics Management team will present the latest developments of the company and will meet with both investors and pharmaceutical firms.About Quantum GenomicsQuantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. The company relies on 20 years of academic research from the Paris-Descartes University and the laboratory directed by Dr. Catherine Llorens-Cortes at the Collège de France (French National Institute of Health and Medical Research (INSERM)/ the Scientific Centre for National Research (CNRS)). The goal of Quantum Genomics is to develop innovative treatments for complicated, or even resistant, cases of hypertension (around 30% of patients have poor control of their condition or receive ineffective treatment) and for heart failure (one in two patients diagnosed with severe heart failure dies within five years).Based in Paris and New York, Quantum Genomics is listed on the Euronext Growth exchange in Paris (FR0011648971- ALQGC) and trades on the OTCQX Best Market in the United States (symbol: QNNTF).For more information, please visit www.quantum-genomics.com, or follow us on Twitter and LinkedInContact information                                                                                                                     Quantum Genomics  Jean-Philippe Milon CEO +33 (0)1 85 34 77 70 | jean-philippe.milon@quantum-genomics.comMarc Karako CFO - Investor Relations +33 (0)1 85 34 77 70 | marc.karako@quantum-genomics.com    So Bang (Europe)   Nathalie Boumendil Financial Communications +33 (0)6 85 82 41 95 | nathalie@so-bang.frSamuel Beaupain Media Relations and Scientific Communications +33 (0)6 88 48 48 02 | samuel@so-bang.fr    LifeSci (USA)  Dan Ferry Financial Communications +1 (617) 535-7746 | Daniel@lifesciadvisors.comMike Tattory Media Relations and Scientific Communications +55 11 3573 6316 | mtattory@lifescipublicrelations.com

  • La Bourse de Paris reprend espoir au sujet du commerce
    AFP

    La Bourse de Paris reprend espoir au sujet du commerce

    La Bourse de Paris a terminé sur une petite avance ("0,18%) mardi, effaçant ses pertes du début de séance après des informations de presse selon lesquelles les Américains seraient prêts à reporter les tarifs douaniers supplémentaires visant des produits chinois prévues le 15 décembre.

  • La Bourse de Paris, sur la défensive, s'enfonce dans le rouge (-0,84%)
    AFP

    La Bourse de Paris, sur la défensive, s'enfonce dans le rouge (-0,84%)

    La Bourse de Paris reculait mardi à la mi-journée (-0,84%), les investisseurs faisant preuve de prudence avant une décision de Donald Trump dans le conflit commercial opposant les Etats-Unis à la Chine et les élections législatives britanniques.

  • Globe Newswire

    Quantum Genomics and Biolab Sanus Pharmaceutical Enter into Exclusive Licensing and Collaboration Agreement for Firibastat in Latin America

    Biolab Sanus Pharmaceutical to receive an exclusive license to develop and commercialize firibastat for the treatment of arterial hypertension in Latin AmericaPARIS and NEW YORK, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat resistant hypertension and heart failure, and Biolab Sanus Pharmaceutical, one of the five largest pharmaceutical companies in Brazil, today announced that they have entered into an exclusive licensing and collaboration agreement to develop and commercialize firibastat in Latin America. This is the first regional partnership for Quantum Genomics. Under the terms of the agreement, Biolab Sanus Pharmaceutical will receive exclusive commercialization rights to firibastat for the treatment of arterial hypertension in Latin America.  Quantum Genomics will receive upfront and milestone payments amounting up to USD 21,2 M, plus royalties on sales. Biolab Sanus Pharmaceutical will fund part of the Phase III study in difficult to treat/resistant hypertension in Latin America as part of the overall pivotal Phase III trial led by Quantum Genomics."With its portfolio of over 140 products and a strong concentration on hypertension, Biolab Sanus Pharmaceutical is the perfect partner for us in the Latin America market. Its extensive and established cardiology sales force will help to ensure that firibastat, if approved, can transform the standard of care for patients suffering from arterial hypertension throughout Latin America and create long-term shareholder value,” said Jean-Philippe Milon, CEO of Quantum Genomics. “We look forward to include Latin America in our global Phase III trial of firibastat in difficult to treat/resistant hypertension.”Cleiton de Castro Marques, CEO of Biolab Sanus Pharmaceutical, added: "The Phase IIb results of firibastat in arterial hypertension are highly encouraging. Firibastat’s activity across historically difficult-to-treat populations, such as elderly, obese, black and Hispanic groups, fits well into our existing cardiology portfolio and we are excited to have the opportunity to bring this potentially transformative drug to the Latin American community.” About Biolab Sanus PharmaceuticalBiolab Sanus Pharmaceutical is one of the largest Brazilian pharmaceutical companies that has built a successful record, permeated by the dedication and prominence in innovation. With a robust portfolio of more than 100 products, Biolab Sanus Pharmaceutical is in constant innovation and committed to the future. Headquartered in Brazil with 4 manufacturing sites and a R&D facility in Toronto, Canada, Biolab Sanus Pharmaceutical is also the absolute market leader in Cardiology and Arterial Hypertension with more than 15% of market share (R$). Spearheading innovative therapeutic class, Biolab Sanus Pharmaceutical is also a top-rated company in different specialties, such as Dermatology, Gynecology, Pediatrics and Orthopedics. Biolab Sanus Pharmaceutical revenue forecast for 2019 is R$ 2,1 billion, around USD 600 M. With over 3,200 employees, Biolab Sanus Pharmaceutical is the fourth biggest sales force in the country fully dedicated to promoting the company's portfolio all over the Brazilian territory.About Quantum GenomicsQuantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. The company relies on 20 years of academic research from the Paris-Descartes University and the laboratory directed by Dr. Catherine Llorens-Cortes at the Collège de France (French National Institute of Health and Medical Research (INSERM)/ the Scientific Centre for National Research (CNRS)). The goal of Quantum Genomics is to develop innovative treatments for complicated, or even resistant, cases of hypertension (around 30% of patients have poor control of their condition or receive ineffective treatment) and for heart failure (one in two patients diagnosed with severe heart failure dies within five years).Based in Paris and New York, Quantum Genomics is listed on the Euronext Growth exchange in Paris (FR0011648971- ALQGC) and trades on the OTCQX Best Market in the United States (symbol: QNNTF).For more information, please visit www.quantum-genomics.com, or follow us on Twitter and LinkedInContact information                                                                                                                     Quantum Genomics  Jean-Philippe Milon CEO +33 (0)1 85 34 77 70 | jean-philippe.milon@quantum-genomics.comMarc Karako CFO - Investor Relations +33 (0)1 85 34 77 70 | marc.karako@quantum-genomics.com So Bang (Europe)   Nathalie Boumendil Financial Communications +33 (0)6 85 82 41 95 | nathalie@so-bang.frSamuel Beaupain Media Relations and Scientific Communications +33 (0)6 88 48 48 02 | samuel@so-bang.fr LifeSci (USA)  Dan Ferry Financial Communications +1 (617) 535-7746| daniel@lifesciadvisors.comMichael Tattory Media Relations and Scientific Communications +1 (646) 751-4362 | mtattory@lifescipublicrelations.com Biolab Sanus Pharmaceutical  Cleiton de Castro Marques CEO +55 11 3573 6012 | ccm@biolabfarma.com.brJosé Roberto da Costa Pereira Business and Innovation Director +55 11 3573 6316 | jroberto@biolabfarma.com.br

  • Cercle Finance

    Quantum Genomics: Invest Securities relève son objectif

    (CercleFinance.com) - La société a annoncé ses résultats financiers du 1er semestre 2019 et fourni une mise à jour des activités. Invest Securities confirme son opinion Achat sur la valeur, avec un objectif ...

  • Globe Newswire

    Quantum Genomics Enters Into Exclusive Negotiations for its First Partnership

    The Company has entered into exclusive negotiations with a leading cardiology laboratory in South America to sign its first regional partnershipPARIS and NEW YORK, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC, OTCQX - QNNTF), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat resistant hypertension and heart failure, has entered into exclusive negotiations with a South American laboratory that is a leader in the field of cardiology, particularly in arterial hypertension. The company anticipates that these negotiations will lead to the signing of a partnership covering Latin America, representing the first regional partnership for Quantum Genomics. "Following discussions with pharmaceutical companies of all sizes working in the field of arterial hypertension, we decided that a regional partnership strategy is the best path forward to creating long-term shareholder value. This strategy enables us to secure the clinical development of our drug by working alongside agile and ambitious pharmaceutical firms for whom the launch of a new treatment for arterial hypertension is strategic," explained Jean-Philippe Milon, CEO of Quantum Genomics.Discussions and exclusive negotiations with a market-leading South American laboratory in the field of cardiology, particularly in the arterial hypertension segment, are progressing. This particularly dynamic laboratory, which operates in a high-potential market, has a portfolio of over 100 products and has signed more than 50 international partnerships in order to provide patients with the best therapeutic innovations available.Once the agreement is complete, the laboratory will support the next steps in the clinical development of firibastat and then will commercialize the drug for arterial hypertension in Latin America."This strategy creates the most value for the shareholders that support us, and best enables us to bring to market a treatment that will improve the lives of millions of patients around the world. We are very pleased to move forward with this partner, whose interests are perfectly aligned with those of Quantum Genomics," concluded Jean-Philippe Milon.About Quantum GenomicsQuantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. The company relies on 20 years of academic research from the Paris-Descartes University and the laboratory directed by Dr. Catherine Llorens-Cortes at the Collège de France (French National Institute of Health and Medical Research (INSERM)/ the Scientific Centre for National Research (CNRS)). The goal of Quantum Genomics is to develop innovative treatments for complicated, or even resistant, cases of hypertension (around 30% of patients have poor control of their condition or receive ineffective treatment) and for heart failure (one in two patients diagnosed with severe heart failure dies within five years).Based in Paris and New York, Quantum Genomics is listed on the Euronext Growth exchange in Paris (FR0011648971- ALQGC) and trades on the OTCQX Best Market in the United States (symbol: QNNTF).For more information, please visit www.quantum-genomics.com, or follow us on Twitter and LinkedInContact informationQuantum Genomics  Jean-Philippe Milon CEO +33 (0)1 85 34 77 70 | jean-philippe.milon@quantum-genomics.comMarc Karako CFO - Investor Relations +33 (0)1 85 34 77 70 | marc.karako@quantum-genomics.com    So Bang (Europe)   Nathalie Boumendil Financial Communications +33 (0)6 85 82 41 95 | nathalie@so-bang.frSamuel Beaupain Media Relations and Scientific Communications +33 (0)6 88 48 48 02 | samuel@so-bang.fr    LifeSci (USA)  Dan Ferry Financial Communications +1 (617) 535-7746 | Daniel@lifesciadvisors.comMichael Tattory Media Relations and Scientific Communications +1 (646) 751-4362 | mtattory@lifescipublicrelations.com

  • Globe Newswire

    Quantum Genomics Reports First Half 2019 Financial Results and Provides Corporate Update

    * Arterial hypertension: preparing for the pivotal Phase III study of firibastat in patients with resistant arterial hypertension            * Heart failure: the first patients were enrolled in June in QUORUM, a Phase IIb study of firibastat in heart failurePARIS and NEW YORK, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC, OTCQX - QNNTF), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat resistant arterial hypertension and heart failure, has released its half-year 2019 financial results that were approved by the Board of Directors on October 2, 2019. The half-year financial report, including the financial statements for the period ending June 30, 2019, associated notes and external auditor’s report are available on the company's website: www.quantum-genomics.com.Jean-Philippe Milon, Chief Executive Officer of Quantum Genomics, said: "Throughout the first half of 2019, we continued to execute upon our BAPAI Fast Growth strategic plan. We continue to make progress in our lead indication and are preparing to initiate our pivotal Phase III study of firibastat in arterial hypertension by the end of the year. Regarding the clinical development of firibastat in heart failure, we have recruited the first patients for the Phase IIb study QUORUM. Finally, we have improved upon the formulation of firibastat and have identified a new extended-release tablet allowing for a single daily dose while providing optimal pharmacokinetics, an important marker for patient adherence to treatment.”Jean-Philippe continued: “At the same time, we are at an advanced stage of discussion with various pharmaceutical laboratories to negotiate either a global partnership or several regional licenses. We plan to keep options open to allow us to choose the best solution both for our shareholders and for patients to whom the potential availability of a new treatment provides great hope."An overall internal financing capacity of €17.4 million as of June 30, 2019The financial statements for the first half of 2019 reflect operating results of -€5.3 million, compared to -€6.8 million one year earlier due to decreased expenses relating to the end of the NEW-HOPE Phase IIb trial.After accounting for a research tax credit of €0.9 million, net income was -€4.1 million, compared to -€6.2 million for the previous year.Free cash flow (net cash flow relating to business operations) was -€6.4 million for the period.At the end of June 2019, shareholders’ equity equaled €11.1 million, with an additional €1.0 million of other equity (conditional advances from Bpifrance).Cash position was €11.6 million, compared to €14.8 million as of December 31, 2018.As of June 30, 2019, the remaining part of the line of funding agreed upon in March 2018 with Kepler Cheuvreux was at €5.8 million, bringing the overall internal funding capacity to €17.4 million.The company has no financial debts and has the funds necessary to meet its obligations for the next 12 months.Summary of financial elements as of June 30, 2019Key figures in €K (French standards)6/30/20196/30/2018 Income284.865.8 Staff costs(1,576.1)(1,207.1) Other operating costs(4,032.8)(5,668.8) Operating income(5,324.1)(6,810.1) Financial earnings5.9(0.1) Pre-tax operating earnings(5,318.2)(6,810.3) Extraordinary earnings 303.9(60.9) Research tax credit885.7663.1 Net income(4,128.5)(6,208.1) Continuing research programs In the field of arterial hypertension, Quantum Genomics is preparing to initiate pivotal Phase III studies of firibastat, the final step before potentially gaining approval from the U.S. Food and Drug Administration (FDA) to begin the process of commercialization. In early September, the company received positive feedback from the FDA regarding the Phase III design and development plan for firibastat in patients with resistant arterial hypertension.In the field of heart failure, Quantum Genomics recruited in June the first patients for the QUORUM Phase IIb trial assessing the efficacy and tolerability of firibastat compared to ramipril1 in patients after acute myocardial infarction. The study, which has an estimated overall cost of €8 million, will be conducted in approximately 40 clinical centers in Europe and the United States with results expected in the second half of 2020.At the same time, Quantum Genomics is conducting a study of firibastat’s potential to safely treat arterial hypertension (in particular, treatment-resistant hypertension) and heart failure in patients with associated renal failure. Positive results from this study could support the use of firibastat in patients with associated renal failure, thereby providing another asset in treating patients with high blood pressure or heart failure and allowing for considerable expansion of the firibastat market.About Quantum GenomicsQuantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. The company relies on 20 years of academic research from the Paris-Descartes University and the laboratory directed by Dr. Catherine Llorens-Cortes at the Collège de France (French National Institute of Health and Medical Research (INSERM)/ the Scientific Centre for National Research (CNRS)). The goal of Quantum Genomics is to develop innovative treatments for complicated, or even resistant, cases of hypertension (around 30% of patients have poor control of their condition or receive ineffective treatment) and for heart failure (one in two patients diagnosed with severe heart failure dies within five years).Based in Paris and New York, Quantum Genomics is listed on the Euronext Growth exchange in Paris (FR0011648971- ALQGC) and trades on the OTCQX Best Market in the United States (symbol: QNNTF).For more information, please visit www.quantum-genomics.com, or follow us on Twitter and LinkedIn                                                 1 Ramipril is an angiotensin converting enzyme (ACE) inhibitor and the standard treatment for heart failure, including in patients who develop heart failure after an acute myocardial infarction.Contact information                                                                                                                     Quantum Genomics  Jean-Philippe Milon CEO +33 (0)1 85 34 77 70 | jean-philippe.milon@quantum-genomics.comMarc Karako CFO - Investor Relations +33 (0)1 85 34 77 70 | marc.karako@quantum-genomics.com So Bang (Europe)   Nathalie Boumendil Financial Communications +33 (0)6 85 82 41 95 | nathalie@so-bang.frSamuel Beaupain Media Relations and Scientific Communications +33 (0)6 88 48 48 02 | samuel@so-bang.fr LifeSci (USA)  Dan Ferry Financial Communications +1 (617) 535-7746 | Daniel@lifesciadvisors.comMichael Tattory Media Relations and Scientific Communications +1 (646) 751-4362 | mtattory@lifescipublicrelations.com

  • Globe Newswire

    Quantum Genomics Launches Study of Firibastat in Patients with Renal Failure

    PARIS and NEW YORK, Sept. 11, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that a directly targets the brain to treat resistant hypertension and heart failure, today announced that it is launching an additional study with firibastat, a first-in-class brain aminopeptidase A inhibitor (BAPAI), in patients with renal failure. The enrollment of the first patient in the study is expected in September 2019 and the results of the study are expected in April 2020. “The analysis of NEW-HOPE, Quantum Genomics’ Phase IIb study of firibastat in hypertension, has demonstrated that firibastat does not negatively impact renal function. This study aims to confirm that firibastat could potentially be used to treat hypertension, in particular, treatment-resistant hypertension or heart failure, even in the case of associated renal failure," said Bruno Besse, M.D., Chief Medical Officer of Quantum Genomics. A drug that can be used even in the case of associated renal failure represents a real benefit for managing hypertensive patients or those with heart failure. If the results of this study are positive, the market for firibastat would be considerably expanded.Renal failure represents a serious and common comorbidity in patients with hypertension, especially in those with resistant hypertension or heart failure, that can often complicate the treatment of high blood pressure. Most of the current treatment options (ACE inhibitors, sartans, diuretics) in these two pathologies present challenges in the case of associated renal failure, and some are contraindicated, such as specific diuretics and spironolactone.Firibastat is very weakly eliminated by the kidneys and as a consequence has not resulted in any decline in renal function in subjects treated in the clinical studies conducted so far.The study (QGC001/1QG4) will examine the safety and tolerance of firibastat in patients with renal failure. The objective of this study, which will cost less than €500K, is to compare the pharmacokinetics and tolerance of a single 500-mg dose of firibastat in 14 healthy volunteers versus 14 patients with severe renal failure. The study will take place at four sites in France and Hungary. All regulatory authorizations have been obtained.Upcoming events in the coming months October 3, 6:00 PM: publication of the results for the first half-year of 2019October 16: company shareholders club evening (date likely to be changed according to events)November 11-13: Bio Europe in HamburgNovember 16-18: American Heart Association (AHA) Congress in PhiladelphiaNovember 20 -21: Jefferies Conference in LondonJanuary 13-16, 2020: JP Morgan/Biotech Showcase Conference in San FranciscoAbout Quantum GenomicsQuantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. The company relies on 20 years of academic research from the Paris-Descartes University and the laboratory directed by Dr. Catherine Llorens-Cortes at the Collège de France (French National Institute of Health and Medical Research (INSERM)/ the Scientific Centre for National Research (CNRS)). The goal of Quantum Genomics is to develop innovative treatments for complicated, or even resistant, cases of hypertension (around 30% of patients have poor control of their condition or receive ineffective treatment) and for heart failure (one in two patients diagnosed with severe heart failure dies within five years).Based in Paris and New York, Quantum Genomics is listed on the Euronext Growth exchange in Paris (FR0011648971- ALQGC) and trades on the OTCQX Best Market in the United States (symbol: QNNTF).For more information, please visit www.quantum-genomics.com, or follow us on Twitter and LinkedInContact information                                                                                                                     Quantum Genomics  Jean-Philippe Milon CEO +33 (0)1 85 34 77 70 | jean-philippe.milon@quantum-genomics.comMarc Karako CFO - Investor Relations +33 (0)1 85 34 77 70 | marc.karako@quantum-genomics.com    So Bang (Europe)   Nathalie Boumendil Financial Communications +33 (0)6 85 82 41 95 | nathalie@so-bang.frSamuel Beaupain Media Relations and Scientific Communications +33 (0)6 88 48 48 02 | samuel@so-bang.fr    LifeSci (USA)  Dan Ferry Financial Communications +1 (617) 535-7746|Daniel@lifesciadvisors.comMichael Tattory Media Relations and Scientific Communications +1 (646) 751-4362 | mtattory@lifescipublicrelations.com

  • Globe Newswire

    Quantum Genomics Announces Positive FDA Feedback on Phase III Program Design of Firibastat in Resistant Arterial Hypertension

    PARIS and NEW YORK, Sept. 02, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class that directly targets the brain to treat resistant arterial hypertension and heart failure, today announced that it met a new milestone of its strategic plan by receiving favourable feedback from the U.S. Food and Drug Administration (FDA) regarding the Company’s Phase III development plan and trial design for firibastat in patients with resistant arterial hypertension. In a previously completed Phase IIb study presented at the American Heart Association (AHA) Scientific Sessions in November 2018, firibastat reached its primary endpoint and significantly lowered blood pressure to clinically relevant levels. Following these positive results, Quantum Genomics met formally with the FDA to potentially advance firibastat into two U.S. Phase III studies, one to evaluate efficacy and another to evaluate safety.“Currently, 150 million people around the globe struggle with difficult-to-control or treatment-resistant arterial hypertension, and often times related complications,” said Jean-Philippe Milon, Chief Executive Officer of Quantum Genomics. “The positive feedback from the FDA regarding our clinical development plan to advance firibastat into Phase III trials in the United States represents a key milestone in the execution of our strategic plan as presented in April 2018. As of today, we have diligently worked to meet these milestones that we have set forth and look forward to meeting the coming ones. The pivotal Phase III efficacy study of firibastat in difficult-to-treat or treatment-resistant arterial hypertension will thus start by the end of 2019 and its results will be available in the second half of 2021.”The Company’s efficacy study, QGC001/3QG1, will be a three-month double-blind, placebo-controlled study assessing the efficacy of firibastat to reduce hypertension in patients with difficult-to-treat or resistant hypertension. QGC001/3QG1 is expected to enroll 500 hypertensive patients with systolic automated office blood pressure (AOBP) above 140 mmHg despite being treated with two (difficult-to-treat) or three anti-antihypertensive classes including a diuretic (resistant). Patients will receive firibastat or placebo on top of their current treatment. The primary endpoint will be change from baseline in systolic AOBP.The Company’s safety study, QGC001/3QG2, will be an open label study assessing the long-term safety of firibastat. QGC001/3QG2 is expected to enroll 750 difficult-to-treat or resistant hypertensive patients with systolic AOBP above 140 mmHg. 650 patients will receive firibastat for six months, and 100 patients will receive firibastat for one year.About Quantum GenomicsQuantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. The company relies on 20 years of academic research from the Paris-Descartes University and the laboratory directed by Dr. Catherine Llorens-Cortes at the Collège de France (French National Institute of Health and Medical Research (INSERM)/ the Scientific Centre for National Research (CNRS)). The goal of Quantum Genomics is to develop innovative treatments for complicated, or even resistant, cases of hypertension (around 30% of patients have poor control of their condition or receive ineffective treatment) and for heart failure (one in two patients diagnosed with severe heart failure dies within five years).Based in Paris and New York, Quantum Genomics is listed on the Euronext Growth exchange in Paris (FR0011648971- ALQGC) and trades on the OTCQX Best Market in the United States (symbol: QNNTF).For more information, please visit www.quantum-genomics.com, or follow us on Twitter and LinkedInContact information                                                                                                                     Quantum Genomics  Jean-Philippe Milon CEO +33 (0)1 85 34 77 70 | jean-philippe.milon@quantum-genomics.comMarc Karako CFO - Investor Relations +33 (0)1 85 34 77 70 | marc.karako@quantum-genomics.com    So Bang (Europe)   Nathalie Boumendil Financial Communications +33 (0)6 85 82 41 95 | nathalie@so-bang.frSamuel Beaupain Media Relations and Scientific Communications +33 (0)6 88 48 48 02 | samuel@so-bang.fr    LifeSci (USA)  Dan Ferry Financial Communications +1 (617) 535-7746 | Daniel@lifesciadvisors.comMichael Tattory Media Relations and Scientific Communications +1 (646) 751-4362 | mtattory@lifescipublicrelations.com

  • Globe Newswire

    Quantum Genomics Announces Result of Annual General Meeting

    PARIS and NEW YORK, June 27, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class that directly targets the brain to treat resistant hypertension and heart failure, informs its shareholders that all proposed resolutions were duly passed at the Annual General Meeting of shareholders and governance held today, June 27. All resolutions were passed almost unanimously, demonstrating shareholders’ support of the Board of Directors' guidance, and confidence in the continued strategic execution by the company.In parallel with this Annual General Meeting, the Board of Directors was informed of the resignation of director Jean-Paul Kress from the Board, a position he has held since June 2018. This resignation follows his appointment on June 24 as Chief Executive Officer of MorphoSys, which is incompatible with the exercise of his mandate with Quantum Genomics.The Board of Directors of Quantum Genomics is now composed of four members, including Jean-Philippe Milon, whose appointment as Director of the Company was approved by the General Meeting today.About Quantum GenomicsQuantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. The company relies on 20 years of academic research from the Paris-Descartes University and the laboratory directed by Dr. Catherine Llorens-Cortes at the Collège de France (French National Institute of Health and Medical Research (INSERM)/ the Scientific Centre for National Research (CNRS)). The goal of Quantum Genomics is to develop innovative treatments for complicated, or even resistant, cases of hypertension (around 30% of patients have poor control of their condition or receive ineffective treatment) and for heart failure (one in two patients diagnosed with severe heart failure dies within five years).Based in Paris and New York, Quantum Genomics is listed on the Euronext Growth exchange in Paris (FR0011648971- ALQGC) and trades on the OTCQX Best Market in the United States (symbol: QNNTF).For more information, please visit www.quantum-genomics.com, or follow us on Twitter and LinkedInContact information                                                                                                                     Quantum Genomics  Jean-Philippe Milon CEO +33 (0)1 85 34 77 70 | jean-philippe.milon@quantum-genomics.comMarc Karako CFO - Investor Relations +33 (0)1 85 34 77 70 | marc.karako@quantum-genomics.com So Bang (Europe)   Nathalie Boumendil Financial Communications +33 (0)6 85 82 41 95 | nathalie@so-bang.frSamuel Beaupain Media Relations and Scientific Communications +33 (0)6 88 48 48 02 | samuel@so-bang.fr LifeSci (USA)  Dan Ferry Financial Communications +1 (617) 535-7746| Daniel@lifesciadvisors.comMichael Tattory Media Relations and Scientific Communications +1 (646) 751-4362 | mtattory@lifescipublicrelations.com

  • Globe Newswire

    Quantum Genomics Announces the Publication of its Phase IIb NEW-HOPE Study Results of Firibastat in Arterial Hypertension in the Journal Circulation

    PARIS and NEW YORK, April 26, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class that directly targets the brain to treat resistant hypertension and heart failure, announces the publication of the full results from its Phase IIb NEW-HOPE study in Circulation, a major peer-reviewed journal of the American Heart Association.The article, co-authored by Keith C. Ferdinand, Fabrice Balavoine, Bruno Besse, Henry R. Black, Stephanie Desbrandes, Howard C. Dittrich and Shawna D. Nesbitt on behalf of the NEW-HOPE Investigators, is entitled “Efficacy and Safety of Firibastat, a First-in-Class Brain Aminopeptidase A Inhibitor, in Hypertensive Overweight Patients of Multiple Ethnic Origins: A Phase 2, Open-Label, Multicenter, Dose-Titrating Study”. The full article has been published online ahead of print and is available on Circulation website (DOI: 10.1161/CIRCULATIONAHA.119.040070).The data reported in this article provide strong evidence of the efficacy of firibastat to decrease blood pressure in a high-risk diverse population with a known reduced response to systemic renin-angiotensin system blockers, such as ACE inhibitors or AT1 receptor blockers. The results support further investigation of firibastat in subjects with difficult-to-treat or resistant hypertension.“Together with the NEW-HOPE Steering Committee, we are very proud of this publication,” said Dr. Bruno Besse, Chief Medical Officer of Quantum Genomics. “Having these impactful results both presented orally in a late-breaking session at the 2018 Scientific Sessions of the American Heart Association and published in the prestigious Circulation journal is a great recognition of the promise of firibastat, which is the first representative of a new class of drugs with a unique mode of action to address unmet needs in difficult-to-treat hypertension. This publication is very encouraging as we continue to focus on the pivotal Phase III trial preparation.”About Quantum GenomicsQuantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. The company relies on 20 years of academic research from the Paris-Descartes University and the laboratory directed by Dr. Catherine Llorens-Cortes at the Collège de France (French National Institute of Health and Medical Research (INSERM)/ the Scientific Centre for National Research (CNRS)). The goal of Quantum Genomics is to develop innovative treatments for complicated, or even resistant, cases of hypertension (around 30% of patients have poor control of their condition or receive ineffective treatment) and for heart failure (one in two patients diagnosed with severe heart failure dies within five years).Based in Paris and New York, Quantum Genomics is listed on the Euronext Growth exchange in Paris (FR0011648971- ALQGC) and trades on the OTCQX Best Market in the United States (symbol: QNNTF).For more information, please visit www.quantum-genomics.com, or follow us on Twitter and LinkedInContact information                                                                                                                     Quantum Genomics  Jean-Philippe Milon CEO +33 (0)1 85 34 77 70 | jean-philippe.milon@quantum-genomics.comMarc Karako CFO - Investor Relations +33 (0)1 85 34 77 70 | marc.karako@quantum-genomics.com    So Bang (Europe)   Nathalie Boumendil Financial Communications +33 (0)6 85 82 41 95 | nathalie@so-bang.frSamuel Beaupain Media Relations and Scientific Communications +33 (0)6 88 48 48 02 | samuel@so-bang.fr    LifeSci (USA)  Dan Ferry Financial Communications +1 (617) 535-7746 | Daniel@lifesciadvisors.comMichael Tattory Media Relations and Scientific Communications +1 (646) 751-4362 | mtattory@lifescipublicrelations.com

  • Globe Newswire

    Quantum Genomics Receives First Regulatory and Ethics Approvals to Initiate Phase IIb QUORUM Study of Firibastat in Heart Failure

    PARIS and NEW YORK, April 17, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth: ALQGC, OTCQX: QNNTF), a biopharmaceutical company specializing in the development of a new drug class that directly targets the brain to treat resistant hypertension and heart failure, today announced the first regulatory and ethics approvals for its Phase IIb QUORUM study of firibastat in heart failure. The French National Agency for Medicines and Health Products Safety (ANSM) in France was the first Health Authority to approve the study which will be conducted in seven European countries (France, Germany, Hungary, Poland, Slovakia, Spain, UK) and in the US.QUORUM (QUantum Genomics QCG001 Or Ramipril after acUte Myocardial infarction to prevent left ventricular dysfunction) is a multi-center, multinational, randomized, double-blind, active-controlled trial with three parallel groups (firibastat 100 mg BID, firibastat 250 mg BID and ramipril 5 mg BID). The study will enroll 294 subjects within 24 hours after Acute Myocardial Infarction (AMI), treated with primary Percutaneous Coronary Intervention (PCI). The aim of the study is to assess the efficacy and the safety of firibastat compared to ramipril1. The primary endpoint will be the change from baseline in Left Ventricle Ejection Fraction (LVEF) assessed by Cardiac Magnetic Resonance (CMR) after a three-month treatment. Other endpoints will include cardiac events, functional status, safety and change in HF biomarkers.Bruno Besse, Chief Medical Officer of Quantum Genomics commented: “Approval by both regulatory authorities and ethics committees is a major milestone for QUORUM. It is the first trial in recent years to study a new therapeutic class instead of Angiotensin-Converting Enzyme (ACE)-inhibitors and not on top of ACE-inhibitors, demonstrating further support for Quantum Genomics’ efforts to deliver on firibastat’s potential as a well-tolerated alternative to the ACE-inhibitors for the treatment of heart failure.”Prof. Gilles Montalescot (Paris, France) is QUORUM’s Principal Investigator and is chairing an international Steering Committee composed of Prof. John H. Alexander (Durham, USA), Prof. Leonardo Bolognese (Florence, Italy), Prof. Angel-Ramon Cequier (Barcelona, Spain) and Prof. Harald Darius (Berlin, Germany).AppendixCardiovascular diseases are the highest cause of mortality in the world, causing 17,7 million deaths, representing 31% of total global mortality.2 In France alone, despite considerable therapeutic progress, cardiovascular diseases are the root cause of around 140,000 deaths per year; they are also one of the main causes of morbidity with 11 million patients treated for vascular risk.3 In total they represent 28 billion euros in annual expenditure. * Heart failure, the largest cause of hospitalization in France among adults40 million4 people suffer from heart failure worldwide and more than 1 million in France alone. The frequency of the disease has doubled in 10 years. Heart failure often results in death and its prognosis is always especially dark. * Restrictive and not always effective treatmentsIn heart failure, different families of treatments can be combined depending on the patient, however morbidity and mortality are not lower: half of the patients die in the 3 to 5 years following onset of the symptoms of heart failure.5The new therapeutic group developed by Quantum Genomics is therefore promising for millions of patients worldwide.About Quantum GenomicsQuantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. The company relies on 20 years of academic research from the Paris-Descartes University and the laboratory directed by Dr. Catherine Llorens-Cortes at the Collège de France (French National Institute of Health and Medical Research (INSERM)/ the Scientific Centre for National Research (CNRS)). The goal of Quantum Genomics is to develop innovative treatments for complicated, or even resistant, cases of hypertension (around 30% of patients have poor control of their condition or receive ineffective treatment) and for heart failure (one in two patients diagnosed with severe heart failure dies within five years).Based in Paris and New York, Quantum Genomics is listed on the Euronext Growth exchange in Paris (FR0011648971- ALQGC) and trades on the OTCQX Best Market in the United States (symbol: QNNTF).For more information, please visit www.quantum-genomics.com, or follow us on Twitter and LinkedIn Contact information                                                                                                                     Quantum Genomics  Jean-Philippe Milon CEO +33 (0)1 85 34 77 70 | jean-philippe.milon@quantum-genomics.comMarc Karako CFO - Investor Relations +33 (0)1 85 34 77 70 | marc.karako@quantum-genomics.com    So Bang (Europe)   Nathalie Boumendil Financial Communications +33 (0)6 85 82 41 95 | nathalie@so-bang.frSamuel Beaupain Media Relations and Scientific Communications +33 (0)6 88 48 48 02 | samuel@so-bang.fr    LifeSci (USA)  Dan Ferry Financial Communications +1 (617) 535-7746| Daniel@lifesciadvisors.comMichael Tattory Media Relations and Scientific Communications +1 (646) 751-4362 | mtattory@lifescipublicrelations.com                                                               1 Ramipril is an Angiotensin-Converting-Enzyme (ACE) inhibitor, reference therapy in heart failure, including patients developing heart failure after acute myocardial infarction2 Source: WHO | Cardiovascular Diseases - Fact sheet - January 20153 Source: French Ministry of Health and Solidarity – Cardiovascular diseases4 Tayal et al. Genome Medicine (2017) 9:205 Source: Novartis, Heart failure and the French: decrypting the perception study “The heart of French people” | Franzin-Garrec M. Heart failure. A chronic disease on an alarming rise

En utilisant Yahoo vous acceptez les cookies de Yahoo/ses partenaires aux fins de personnalisation et autres usages